Faculty Publications
Permanent URI for this communityhttp://192.168.24.11:4000/handle/123456789/7
Scholarly Publications by Integral Academia
Browse
3 results
Search Results
Item Neuroinflammation and Immunomodulation Via Nano- Therapeutics(Deep Science Publishing, 2025) Mariya Fatima, Mansi Srivastava, Ahmad Aleem, Hasnain Raza, Mohd Aftab SiddiquiNeuroinflammation is a characteristic of disorders of the central nervous system (CNS) including Alzheimer, Parkinson, multiple sclerosis, traumatic brain injury, and stroke. The key processes that cause it are: microglial and astrocytic inflammation, cytokine production imbalance, oxidative stress, mitochondrial dysfunction, and dysfunction of the bloodbrain barrier (BBB). The traditional therapy measures are not effective since the trip rarely enters into the BBB, there is always a possibility of toxicity in the body, and the target is not selective. Drug delivery strategies developed through nanotechnology will provide new solutions because it allows the targeted delivery to the CNS, regulated drug release and a controllable response to the immune system. Lipid-based nanoparticles, polymeric carriers, inorganic nanomaterials, dendrimers, and nanogels have shown efficacy in preclinical studies with lowering of pro-inflammatory cytokines, increased antioxidant defenses, silencing of pathogenic genes, as well as repair of BBB integrity. Initial clinical trials on nanoformulations of curcumin, methylprednisolone, and glatiramer acetate show have shown enhanced safety, as well as therapeutic outcome in nanoformulations over traditional medications. Nevertheless, the issue of toxicity, lasting biodistribution and regulatory standardization continues to be such stumbling blocks. New directions related to biomimetic nanocarriers, stimuli-sensitive systems, and CRISPR based nano-delivery vectors appear to promise accuracy in nanomedicine in relation to neuroinflammation. The present review summarizes the molecular pathways involved in neuroinflammation, current nano-therapies, preclinical and clinical data, and the challenges and future directions that are necessary to convert nanomedicine to clinical neurotherapies.Item Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease(Academic Press, 2023) Aditya Singh; Ashwini Gawade , Satish Polshettiwar , Hetal Hingalajia , Bhupendra Gopalbhai PrajapatiExtracellular amyloid-(A) plaques and neurofibrillary in the intracellular environment are defining characteristics of Alzheimer's disease (AD), neuronal death, and synaptic loss, all of which contribute to progressive cognitive impairment. Age is the most significant risk factor for AD, with AD prevalence exponentially increasing after age 65. As the average lifespan in emerging countries rises, it is anticipated that the total prevalence of AD will double during the next 20 years. Effective drug delivery to the target tissue, constant therapeutic drug concentrations, a lowering in dosing quantity and frequency, and increased patient compliance are all qualities of ideal drug delivery systems which depend on Pharmacokinetics and Pharmacodynamic of Various novel formulations Targeting AD. Currently different formulations of Donepezil Hydrochloride; Memantine Hydrochloride are available in market such tablets orally disintegrant, Capsule extended release and lots of attempts are going on in term of different delivery system like liposomal drug delivery, nose to brain delivery system, nanoformulations having different nanocarriers for the treatment of AD. Fate of all the novel formulations depends on the Pharmacokinetics and Pharmacodynamic behavior of the drug substances. Pharmacokinetics (PK) studies the disposition of drug molecules in the body, including their concentration patterns and AUC last, Tmax, Cmax, and AUC inf values Pharmacodynamic (PD) assessment looks at how a drug affects the body. includes variations in Emax, EC50, in an Emax-model parameter. A drug must cross the blood brain barriers and be absorbed by the specific tissues in order for it to be effective in treating an Alzheimer patient (as measured by PK studies). To successfully alter the target protein activity in the body (as determined by PD studies), this is required. This chapter will focus on the various novel formulations Targeting AD and its Pharmacokinetics and Pharmacodynamics behavior.Item Dendrimers in the management of Alzheimer's disease(Academic Press, 2024) Aditya Singh; Chetna Modi , Bhupendra Gopalbhai Prajapati , Sudarshan Singh , Shubhrat MaheshwariAlzheimer's disease (AD) is a progressive neurological disorder that affects the brain and leads to decline in cognitive function, memory, thinking, behavior. Alzheimer's disease is the most common cause of dementia, accounting for 60%–80% of all cases. The exact cause of AD is still not fully, however it is thought to involve a combination of genetic, environmental, and lifestyle factors. There is currently no exact medication and drug delivery available that can cure for AD, but there are several treatments available that can help in managing symptoms and slow the progression of the disease. These treatments include medication, behavioral interventions, and lifestyle changes, such as exercise and a healthy diet. Additionally, ongoing research is focused on developing nanotechnology-based new therapies and approaches such as nanoparticles, solid lipid nanoparticles, vesicular drug delivery, and dendrimers to prevent, slow, or cure AD. with Dendrimers in AD act as carrier for drug that target the β-amyloid plaques and T-tangles that are characteristic of the characteristic of the disease. Dendrimers can conjugate with drugs, enabling them to be delivered to the brain and penetrate the blood-brain barrier. Moreover, dendrimers have been reported as imaging agent that help in detection and monitoring the progression of AD. In this chapter a brief overview on dendrimers synthesis, characterization, and conjugation with drugs for treatment and management AD elaborated.